Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease
Sodium-glucose cotransporter inhibitors updated their position in the therapy of patients with type 2 diabetes mellitus due to proven nephro- and cardioprotective effects. The DAPA-CKD study, performed among individuals with CKD of various etiologies, was also conducted in a mixed population, includ...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2022-11-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/108317/pdf |
| _version_ | 1811186773823324160 |
|---|---|
| author | Minara S. Shamkhalova Olga Y. Sukhareva Marina V. Shestakova |
| author_facet | Minara S. Shamkhalova Olga Y. Sukhareva Marina V. Shestakova |
| author_sort | Minara S. Shamkhalova |
| collection | DOAJ |
| description | Sodium-glucose cotransporter inhibitors updated their position in the therapy of patients with type 2 diabetes mellitus due to proven nephro- and cardioprotective effects. The DAPA-CKD study, performed among individuals with CKD of various etiologies, was also conducted in a mixed population, including patients without type 2 diabetes, showed the ability of dapagliflozin to reduce the risk of the primary combined endpoint (eGFR15 ml/min/1.73 m2, the need for chronic dialysis or kidney transplantation, time to renal or cardiovascular death), and certain secondary endpoints. Due to the inclusion of dapagliflozin into the treatment of the patients with CKD of not only the diabetic origin and the expected subsequent significant expansion of the patient population with indications for the use of this drug, the review of the results of the sub-analyses of DAPA-CKD study may be of interest to the clinicians. |
| first_indexed | 2024-04-11T13:51:00Z |
| format | Article |
| id | doaj.art-c62424041fe7406a9b8a1c75d1793a21 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-04-11T13:51:00Z |
| publishDate | 2022-11-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-c62424041fe7406a9b8a1c75d1793a212022-12-22T04:20:38Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422022-11-0194101188119610.26442/00403660.2022.10.20188378200Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney diseaseMinara S. Shamkhalova0https://orcid.org/0000-0002-3433-0142Olga Y. Sukhareva1https://orcid.org/0000-0002-3443-7206Marina V. Shestakova2https://orcid.org/0000-0002-5057-127XEndocrinology Research CentreNational Medical Research Center for EndocrinologyEndocrinology Research CentreSodium-glucose cotransporter inhibitors updated their position in the therapy of patients with type 2 diabetes mellitus due to proven nephro- and cardioprotective effects. The DAPA-CKD study, performed among individuals with CKD of various etiologies, was also conducted in a mixed population, including patients without type 2 diabetes, showed the ability of dapagliflozin to reduce the risk of the primary combined endpoint (eGFR15 ml/min/1.73 m2, the need for chronic dialysis or kidney transplantation, time to renal or cardiovascular death), and certain secondary endpoints. Due to the inclusion of dapagliflozin into the treatment of the patients with CKD of not only the diabetic origin and the expected subsequent significant expansion of the patient population with indications for the use of this drug, the review of the results of the sub-analyses of DAPA-CKD study may be of interest to the clinicians.https://ter-arkhiv.ru/0040-3660/article/viewFile/108317/pdfsglt-2 inhibitordapagliflozindapa-ckd studychronic kidney disease |
| spellingShingle | Minara S. Shamkhalova Olga Y. Sukhareva Marina V. Shestakova Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease Терапевтический архив sglt-2 inhibitor dapagliflozin dapa-ckd study chronic kidney disease |
| title | Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease |
| title_full | Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease |
| title_fullStr | Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease |
| title_full_unstemmed | Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease |
| title_short | Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease |
| title_sort | sub analyses of the dapa ckd study new data on the use of sodium glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease |
| topic | sglt-2 inhibitor dapagliflozin dapa-ckd study chronic kidney disease |
| url | https://ter-arkhiv.ru/0040-3660/article/viewFile/108317/pdf |
| work_keys_str_mv | AT minarasshamkhalova subanalysesofthedapackdstudynewdataontheuseofsodiumglucosecotransportertype2inhibitorinthetreatmentofchronickidneydisease AT olgaysukhareva subanalysesofthedapackdstudynewdataontheuseofsodiumglucosecotransportertype2inhibitorinthetreatmentofchronickidneydisease AT marinavshestakova subanalysesofthedapackdstudynewdataontheuseofsodiumglucosecotransportertype2inhibitorinthetreatmentofchronickidneydisease |